Ubiquitin-Dependent 26S Proteasomal Pathway: A Role in the Degradation of Native Human Liver CYP3A4 Expressed in Saccharomyces Cerevisiae?

doi:10.1006/abbi.2001.2482

Archives of Biochemistry and Biophysics

Volume 393, Issue 1, 1 September 2001, Pages 106-116

https://doi.org/10.1006/abbi.2001.2482 Get rights and content

Abstract

Cytochrome P450, CYP3A4, is the dominant human liver endoplasmic reticulum (ER) hemoprotein enzyme, responsible for the metabolism of over 60% of clinically relevant drugs. We have previously shown that mechanism-based suicide inactivation of CYP3A4 and its rat liver ER orthologs, CYPs 3A, via heme-modification of their protein moieties, results in their ubiquitin (Ub)-dependent 26S proteasomal degradation (Korsmeyer et al. (1999) Arch. Biochem. Biophys. 365, 31; Wang et al. (1999) Arch. Biochem. Biophys. 365, 45). This is not surprising given that the heme-modified CYP3A proteins are structurally damaged. To determine whether the turnover of the native enzyme similarly recruited this pathway, we heterologously expressed this protein in wild-type Saccharomyces cerevisiae and mutant strains (hrd1Δ, hrd2-1, and hrd3Δ) previously shown to be deficient in the Ub-dependent 26S proteasomal degradation of the polytopic ER protein 3-hydroxy-3-methylglutaryl-CoA reductase (isoform Hmg2p), the rate-limiting enzyme in sterol biosynthesis, as well as in strains deficient in ER-associated Ub-conjugating enzymes, Ubc6p and/or Ubc7p (Hampton et al. (1996) Mol. Biol. Cell 7, 2029; Hampton and Bhakta (1997) Proc. Natl. Acad. Sci. USA 94, 12,944). Our findings reveal that in common with the degradation of Hmg2p, that of native CYP3A4 also requires Hrd2p (a subunit of the 19S cap complex of the 26S proteasome) and Ubc7p, and to a much lesser extent Hrd3p, a component of the ER-associated Ub-ligase complex. In contrast to Hmg2p-degradation, that of native CYP3A4 does not appear to absolutely require Hrd1p, another component of the ER-associated Ub–ligase complex. Furthermore, studies in a S. cerevisiae pep4Δ strain proven to be deficient in the vacuolar degradation of carboxypeptidase Y indicated that CYP3A4 degradation is also largely independent of vacuolar (lysosomal) proteolytic function. The degradation of two other native ER proteins, Sec61p and Sec63p, normal components of the ER translocon, were also examined in parallel and found to be stabilized to some extent in HRD2- and UBC7-deficient strains. Together these findings attest to the remarkable mechanistic diversity in the normal degradation of ER proteins.

References (66)

D.R. Nelson et al.
J. Biol. Chem.
(1988)
M.A. Correia et al.
Arch. Biochem. Biophys.
(1987)
M.A. Correia et al.
Arch. Biochem. Biophys.
(1992)
M.A. Correia et al.
Arch. Biochem. Biophys.
(1992)
H. Wang et al.
Arch. Biochem. Biophys.
(1999)
K.K. Korsmeyer et al.
Arch. Biochem. Biophys.
(1999)
R.G. Gardner et al.
J. Biol. Chem.
(1999)
S. Song et al.
Neurosci. Lett.
(2000)
P. Chen et al.
Cell
(1993)
E.W. Jones
Methods Enzymol.
(1991)

P. Chomczynski et al.

Anal. Biochem.

(1987)

B.J. Roberts

J. Biol. Chem.

(1997)

D.S. Riddick et al.

Biochem. Pharmacol.

(1990)

M. Delaforge et al.

Biochem. Pharmacol.

(1983)

P.B. Watkins et al.

J. Biol. Chem.

(1986)

M.A. Correia

Methods. Enzymol.

(1991)

D.J. Tierney et al.

Arch. Biochem. Biophys.

(1992)

B.J. Roberts et al.

J. Biol. Chem.

(1995)

M.X. Yang et al.

Archiv. Biochem. Biophys.

(1997)

F.P. Guengerich

Mammalian Cytochromes P450

(1987)

S.A. Wrighton et al.

Crit. Rev. Toxicol.

(1992)

F.P. Guengerich

P.R. Ortiz de Montellano

M.A. Correia

C. De Lemos-Chiarandini et al.

J. Cell Biol.

(1987)

S. Monier et al.

J. Cell Biol.

(1988)

B. Kemper et al.

Drug Metab. Rev.

(1989)

T. Sato et al.

EMBO J.

(1990)

R.J. Edwards et al.

Biochemistry

(1991)

M. Sakaguchi et al.

S.D. Black et al.

Biochemistry

(1994)

P.R. Ortiz de Montellano et al.

Cited by (39)

Drug Metabolism: Cytochrome P450
2022, Comprehensive Pharmacology
Cytochrome P450 (P450 or CYP) enzymes are the major catalysts of oxidation of all drugs. Of the 57 human P450, 2/3 have been demonstrated to be capable of oxidizing or reducing some drugs but P450s 1A2, 2C9, 2C19, 2D6, and 3A4 are involved in most drug oxidations. Some other P450s can also be involved, and even some P450s whose roles are mainly in steroid metabolism can oxidize drugs (e.g., 11A1, 46A1). P450s are regulated by a number of factors and by genetics, inducers, and inhibitors. Thus, individuals vary considerably in drug metabolism by P450s, and P450s are a major basis for idiosyncratic drug responses and drug-drug interactions. Knowledge about P450s has led to better pre-clinical approaches to human pharmacokinetic and drug safety issues. The general mechanism of drug oxidation involves a chemical intermediate in P450 reactions termed Compound I (formally FeO³⁺). Consideration of basic kinetic schemes with P450s reveals several interesting features, some of which can lead to issues in extrapolation and to problems in the analysis of inhibitor data. At least 40% of the human P450s now have X-ray crystal structures available. Due to the conformational flexibility of P450s the de novo prediction of catalytic selectivity is still challenging.
Human liver cytochrome P450 3A4 ubiquitination: Molecularrecognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes
2015, Journal of Biological Chemistry
CYP3A4 is an abundant and catalytically dominant human liver endoplasmic reticulum-anchored cytochrome P450 enzyme engaged in the biotransformation of endo- and xenobiotics, including >50% of clinically relevant drugs. Alterations of CYP3A4 protein turnover can influence clinically relevant drug metabolism and bioavailability and drug-drug interactions. This CYP3A4 turnover involves endoplasmic reticulum-associated degradation via the ubiquitin (Ub)-dependent 26 S proteasomal system that relies on two highly complementary E2 Ub-conjugating-E3 Ub-ligase (UBC7-gp78 and UbcH5a-C terminus of Hsc70-interacting protein (CHIP)-Hsc70-Hsp40) complexes, as well as protein kinases (PK) A and C. We have documented that CYP3A4 Ser/Thr phosphorylation (Ser(P)/Thr(P)) by PKA and/or PKC accelerates/enhances its Lys ubiquitination by either of these E2-E3 systems. Intriguingly, CYP3A4 Ser(P)/Thr(P) and ubiquitinated Lys residues reside within the cytosol-accessible surface loop and/or conformationally assembled acidic Asp/Glu clusters, leading us to propose that such post-translational Ser/Thr protein phosphorylation primes CYP3A4 for ubiquitination. Herein, this possibility was examined through various complementary approaches, including site-directed mutagenesis, chemical cross-linking, peptide mapping, and LC-MS/MS analyses. Our findings reveal that such CYP3A4 Asp/Glu/Ser(P)/Thr(P) surface clusters are indeed important for its intermolecular electrostatic interactions with each of these E2-E3 subcomponents. By imparting additional negative charge to these Asp/Glu clusters, such Ser/Thr phosphorylation would generate P450 phosphodegrons for molecular recognition by the E2-E3 complexes, thereby controlling the timing of CYP3A4 ubiquitination and endoplasmic reticulum-associated degradation. Although the importance of phosphodegrons in the CHIP targeting of its substrates is known, to our knowledge this is the first example of phosphodegron involvement in gp78-substrate recruitment, an important step in CYP3A4 proteasomal degradation.
Background: CYP3A4, a major human liver drug-metabolizing enzyme, is degraded upon phosphorylation and ubiquitination.
Results: CYP3A4 phosphorylation occurs within negatively charged surface clusters that are important for electrostatic interactions with positively charged patches of the ubiquitination enzymes.
Conclusion: These phosphorylated clusters enhance CYP3A4 molecular recognition by the ubiquitination complexes.
Significance: This is the first mechanistic example of UBC7-gp78 substrate recognition.
Liver Cytochrome P450 3A endoplasmic reticulum-associated degradation: A major role for the P97 AAA ATPase in cytochrome P450 3A extraction into the cytosol
2011, Journal of Biological Chemistry
The CYP3A subfamily of hepatic cytochromes P450, being engaged in the metabolism and clearance of >50% of clinically relevant drugs, can significantly influence therapeutics and drug-drug interactions. Our characterization of CYP3A degradation has indicated that CYPs 3A incur ubiquitin-dependent proteasomal degradation (UPD) in an endoplasmic reticulum (ER)-associated degradation (ERAD) process. Cytochromes P450 are monotopic hemoproteins N-terminally anchored to the ER membrane with their protein bulk readily accessible to the cytosolic proteasome. Given this topology, it was unclear whether they would require the AAA-ATPase p97 chaperone complex that retrotranslocates/dislocates ubiquitinated ER-integral and luminal proteins into the cytosol for proteasomal delivery. To assess the in vivo relevance of this p97-CYP3A association, we used lentiviral shRNAs to silence p97 (80% mRNA and 90% protein knockdown relative to controls) in sandwich-cultured rat hepatocytes. This extensive hepatic p97 knockdown remarkably had no effect on cellular morphology, ER stress, and/or apoptosis, despite the well recognized strategic p97 roles in multiple important cellular processes. However, such hepatic p97 knockdown almost completely abrogated CYP3A extraction into the cytosol, resulting in a significant accumulation of parent and ubiquitinated CYP3A species that were firmly ER-tethered. Little detectable CYP3A accumulated in the cytosol, even after concomitant inhibition of proteasomal degradation, thereby documenting a major role of p97 in CYP3A extraction and delivery to the 26 S proteasome during its UPD/ERAD. Intriguingly, the accumulated parent CYP3A was functionally active, indicating that p97 can regulate physiological CYP3A content and thus influence its clinically relevant function.
Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: Physiological and pharmacological relevance
2010, Journal of Biological Chemistry
Citation Excerpt :
Accordingly, our studies of heterologous expression of CYP3A4 in wild type Saccharomyces cerevisiae and mutants containing defined genetic lesions in various ERAD components have enabled us to characterize CYP3A ERAD/UPD by identifying several participants such as the ERAD-associated soluble E2 Ub-conjugating enzyme Ubc7p and its membrane anchor Cue1p, Cdc48p-Ufd1p-Npl4 AAA-ATPase complex (homologous to the mammalian p97 complex), and Rpn1p (Hrd2p), an essential 26S proteasomal cap subunit, as important participants in CYP3A ERAD (13, 14, 17). Despite the unambiguous finding that CYP3A4 is indeed degraded in an Ubc7p/Cue1p- and Rpn1p-dependent ERAD process (14, 17), none of the canonical yeast E3 Ub-ligases such as Doa10p or even Hrd1p/Hrd3p involved in the ERAD of several integral and lumenal ER proteins and/or cytosolic proteins (19–27) could be implicated (13, 14, 17). Because this could reflect subtle differences in the recognition of a mammalian CYP3A protein by these yeast Ub-ligases, we examined in vitro CYP3A4 ubiquitination systems functionally reconstituted with purified, recombinant mammalian E2-E3 enzymes.
CYP3A4 is a dominant human liver cytochrome P450 enzyme engaged in the metabolism and disposition of >50% of clinically relevant drugs and held responsible for many adverse drug-drug interactions. CYP3A4 and its mammalian liver CYP3A orthologs are endoplasmic reticulum (ER)-anchored monotopic proteins that undergo ubiquitin (Ub)-dependent proteasomal degradation (UPD) in an ER-associated degradation (ERAD) process. These integral ER proteins are ubiquitinated in vivo, and in vitro studies have identified the ER-integral gp78 and the cytosolic co-chaperone, CHIP (C terminus of Hsp70-interacting protein), as the relevant E3 Ub-ligases, along with their cognate E2 Ub-conjugating enzymes UBC7 and UbcH5a, respectively. Using lentiviral shRNA templates targeted against each of these Ub-ligases, we now document that both E3s are indeed physiologically involved in CYP3A ERAD/UPD in cultured rat hepatocytes. Accordingly, specific RNAi resulted in ≈80% knockdown of each hepatic Ub-ligase, with a corresponding ≈2.5-fold CYP3A stabilization. Surprisingly, however, such stabilization resulted in increased levels of functionally active CYP3A, thereby challenging the previous notion that E3 recognition and subsequent ERAD of CYP3A proteins required ab initio their structural and/or functional inactivation. Furthermore, coexpression in HepG2 cells of both CYP3A4 and gp78, but not its functionally inactive RING-finger mutant, resulted in enhanced CYP3A4 loss greater than that in corresponding cells expressing only CYP3A4. Stabilization of a functionally active CYP3A after RNAi knockdown of either of the E3s, coupled with the increased CYP3A4 loss on gp78 or CHIP coexpression, suggests that ERAD-associated E3 Ub-ligases can influence clinically relevant drug metabolism by effectively regulating the physiological CYP3A content and consequently its function.
CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases
2009, Archives of Biochemistry and Biophysics
Human liver CYP3A4 is an endoplasmic reticulum (ER)-anchored hemoprotein responsible for the metabolism of >50% of clinically prescribed drugs. After heterologous expression in Saccharomyces cerevisiae, it is degraded via the ubiquitin (Ub)-dependent 26S proteasomal pathway that utilizes Ubc7p/Cue1p, but none of the canonical Ub-ligases (E3s) Hrd1p/Hrd3p, Doa10p, and Rsp5p involved in ER-associated degradation (ERAD). To identify an Ub-ligase capable of ubiquitinating CYP3A4, we examined various in vitro reconstituted mammalian E3 systems, using purified and functionally characterized recombinant components. Of these, the cytosolic domain of the ER-protein gp78, also known as the tumor autocrine motility factor receptor (AMFR), an UBC7-dependent polytopic RING-finger E3, effectively ubiquitinated CYP3A4 in vitro, as did the UbcH5a-dependent cytosolic E3 CHIP. CYP3A4 immunoprecipitation coupled with anti-Ub immunoblotting analyses confirmed its ubiquitination in these reconstituted systems. Thus, both UBC7/gp78 and UbcH5a/CHIP may be involved in CYP3A4 ERAD, although their relative physiological contribution remains to be established.
A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation
2009, Journal of Biological Chemistry
Citation Excerpt :
Cycloheximide can perturb cellular physiology via translational shut-off of protein synthesis during the relatively longer time courses required to monitor P450 degradation thereby altering this process (58, 59). A regulatable promoter such as GAL1–10 would be ideal, but then in yeast, P450s, including CYP3A4, are very poorly expressed from plasmids under such promoters (4, 5, 60). For these combined reasons, P450 degradation was as described previously (4, 5), monitored by the stationary chase analyses.
Cytochromes P450 (P450s) incur phosphorylation. Although the precise role of this post-translational modification is unclear, marking P450s for degradation is plausible. Indeed, we have found that after structural inactivation, CYP3A4, the major human liver P450, and its rat orthologs are phosphorylated during their ubiquitin-dependent proteasomal degradation. Peptide mapping coupled with mass spectrometric analyses of CYP3A4 phosphorylated in vitro by protein kinase C (PKC) previously identified two target sites, Thr²⁶⁴ and Ser⁴²⁰. We now document that liver cytosolic kinases additionally target Ser⁴⁷⁸ as a major site. To determine whether such phosphorylation is relevant to in vivo CYP3A4 degradation, wild type and CYP3A4 with single, double, or triple Ala mutations of these residues were heterologously expressed in Saccharomyces cerevisiae pep4Δ strains. We found that relative to CYP3A4wt, its S478A mutant was significantly stabilized in these yeast, and this was greatly to markedly enhanced for its S478A/T264A, S478A/S420A, and S478A/T264A/S420A double and triple mutants. Similar relative S478A/T264A/S420A mutant stabilization was also observed in HEK293T cells. To determine whether phosphorylation enhances CYP3A4 degradation by enhancing its ubiquitination, CYP3A4 ubiquitination was examined in an in vitro UBC7/gp78-reconstituted system with and without cAMP-dependent protein kinase A and PKC, two liver cytosolic kinases involved in CYP3A4 phosphorylation. cAMP-dependent protein kinase A/PKC-mediated phosphorylation of CYP3A4wt but not its S478A/T264A/S420A mutant enhanced its ubiquitination in this system. Together, these findings indicate that phosphorylation of CYP3A4 Ser⁴⁷⁸, Thr²⁶⁴, and Ser⁴²⁰ residues by cytosolic kinases is important both for its ubiquitination and proteasomal degradation and suggest a direct link between P450 phosphorylation, ubiquitination, and degradation.

View all citing articles on Scopus

¹: To whom correspondence should be addressed at Department of Cellular and Molecular Pharmacology, Box 0450, University of California, San Francisco, San Francisco, CA 94143-0450. Fax: 415-476-5292. E-mail: [email protected].

View full text

Regular ArticleUbiquitin-Dependent 26S Proteasomal Pathway: A Role in the Degradation of Native Human Liver CYP3A4 Expressed in Saccharomyces Cerevisiae?

Abstract

J. Biol. Chem.

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.

J. Biol. Chem.

Neurosci. Lett.

Cell

Methods Enzymol.

Anal. Biochem.

J. Biol. Chem.

Biochem. Pharmacol.

Biochem. Pharmacol.

J. Biol. Chem.

Methods. Enzymol.

Arch. Biochem. Biophys.

J. Biol. Chem.

Archiv. Biochem. Biophys.

Mammalian Cytochromes P450

Crit. Rev. Toxicol.

J. Cell Biol.

J. Cell Biol.

Drug Metab. Rev.

EMBO J.

Biochemistry

Biochemistry

Regular Article
Ubiquitin-Dependent 26S Proteasomal Pathway: A Role in the Degradation of Native Human Liver CYP3A4 Expressed in Saccharomyces Cerevisiae?